BHCHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Bausch Health Cos., Inc. hold a median 12-month price target of $7 — +0.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 1 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Bausch Health Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (40): The shares have been drifting down relative to others.
Size (32): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Bausch Health Cos., Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on BHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits 0.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Apr 2026 | RBC Capital | Maintains | Sector Perform | $10 → $9.00 |
| 25 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Jan 2026 | Truist Securities | Maintains | Hold | — |
| 9 Dec 2025 | Barclays | Initiates | Equal-Weight | — |
| 2 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 6 Feb 2025 | Jefferies | Downgrade | Hold | — |
| 30 Jan 2025 | RBC Capital | Maintains | Sector Perform | — |
| 1 Nov 2024 | RBC Capital | Maintains | Sector Perform | — |
| 2 Aug 2024 | Piper Sandler | Downgrade | Underweight | — |
| 2 Aug 2024 | RBC Capital | Maintains | Sector Perform | — |
| 25 July 2024 | Truist Securities | Maintains | Hold | — |
| 10 July 2024 | Raymond James | Initiates | Market Perform | — |
| 23 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 12 Apr 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 5 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 23 Feb 2024 | RBC Capital | Maintains | Sector Perform | — |
| 20 Sept 2023 | Jefferies | Upgrade | Buy | — |
| 16 June 2023 | TD Cowen | Downgrade | Market Perform | — |
| 22 May 2023 | Jefferies | Maintains | Buy | — |
| 5 May 2023 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 91% of US stocks
Cheaper than 95% of US stocks
Cheaper than 52% of US stocks
Higher than 61% of US stocks
Higher than 83% of US stocks
Higher than 86% of US stocks
Higher than 86% of US stocks
Higher than 20% of US stocks
Higher than 92% of US stocks
Higher than 84% of US stocks
Higher than 97% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| BHCBausch Health Cos., Inc. | $2.6B | 95 |
| SUPNSupernus Pharmaceuticals, Inc. | $2.6B | 80 |
| PBHPrestige Consumer Healthcare, Inc. | $2.4B | 73 |
| RGCRegencell Bioscience Holdings Ltd. | $3.1B | 4 |
| BCRXBioCryst Pharmaceuticals, Inc. | $2.2B | 91 |
| AMLXAmylyx Pharmaceuticals, Inc. | $2.2B | 60 |
| ANIPANI Pharmaceuticals, Inc. | $1.8B | 99 |
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHC appears on the weeks it earns a place.
Bausch Health exceeded Q2 earnings estimates, driven by growth at Salix, Solta Medical, and Bausch + Lomb, prompting the company to raise its 2026 revenue and EBITDA guidance.
Why it matters — The raised 2026 guidance signals improved confidence in the company's outlook, which is a key development for shareholders and analysts following BHC.
Seeking Alpha published the transcript of Bausch Health Companies Inc.'s Q2 2026 earnings call.
Why it matters — Earnings call transcripts provide a detailed record of management's discussion of quarterly results, strategy, and outlook, which BHC watchers rely on for fundamental analysis.
Bausch Health (BHC) reported second-quarter earnings of $1.26 per share, surpassing the Zacks Consensus Estimate of $0.96 per share and up from $0.90 per share a year ago.
Why it matters — The earnings beat indicates Bausch Health's quarterly performance exceeded analyst expectations and improved year over year.
Bausch Health reported second-quarter results, with management noting 13 consecutive quarters of revenue and adjusted EBITDA growth, driven by its Salix, international and Solta Medical businesses.
Why it matters — The extended streak of revenue and EBITDA growth signals sustained operational momentum across key business segments for Bausch Health.
Bausch Health (BHC) reported its Q2 earnings for the period ending June 2026, with the article noting that key metrics should be compared against Wall Street estimates and prior-year figures.
Why it matters — This earnings report provides a performance snapshot that BHC watchers can use to gauge how the company's core business metrics stack up against analyst expectations and historical results.
The 7 Wall Street analysts covering Bausch Health Cos., Inc. have a median 12-month price target of $7, with estimates ranging from $6.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Bausch Health Cos., Inc., 0 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bausch Health Cos., Inc. 95 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Bausch Health Cos., Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +0.0% from the last close, and Ticker Nerd's factor model ranks Bausch Health Cos., Inc. 95 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bausch Health Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $9 over the next 12 months.
Bausch Health Cos., Inc. returned +22.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices.
The most recent item we track (Zacks Investment Research, 30 July 2026): "BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised". Bausch Health exceeded Q2 earnings estimates, driven by growth at Salix, Solta Medical, and Bausch + Lomb, prompting the company to raise its 2026 revenue and EBITDA guidance.
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.
CEO Mr. Thomas J. Appio · 20,300 employees · Canada · https://www.bauschhealth.com